Reuters logo
BRIEF-3SBio Inc says 601a approved by China FDA for clinical trials ​
11. Oktober 2017 / 15:17 / vor einem Monat

BRIEF-3SBio Inc says 601a approved by China FDA for clinical trials ​

Oct 11 (Reuters) - 3SBio Inc

* Recombinant humanized anti-VEGF monoclonal antibody for injection (601a) approved by China FDA for clinical trials ​ Source text for Eikon: Further company coverage:

Unsere Werte:Die Thomson Reuters Trust Principles
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below